Novavax Inc. logo

Novavax Inc. (NVAX)

Market Closed
4 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
10. 19
-0.01
-0.098%
$
1.8B Market Cap
- P/E Ratio
- Div Yield
5.23M Volume
-4.28 Eps
$ 10.2
Previous Close
Add Transaction
Day Range
10.1 10.59
Year Range
6.13 11.97
Want to track NVAX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
An Investigation Has Commenced on Behalf of Novavax, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your NVAX Losses

An Investigation Has Commenced on Behalf of Novavax, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your NVAX Losses

NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.

Accesswire | 1 year ago
Levi & Korsinsky Reminds Shareholders of an Investigation into Novavax, Inc. (NVAX) Regarding Potential Securities Fraud Allegations

Levi & Korsinsky Reminds Shareholders of an Investigation into Novavax, Inc. (NVAX) Regarding Potential Securities Fraud Allegations

NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.

Accesswire | 1 year ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ: NVAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Accesswire | 1 year ago
Did Novavax, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- NVAX

Did Novavax, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- NVAX

NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.

Accesswire | 1 year ago
Novavax, UK terminate vaccine supply agreement

Novavax, UK terminate vaccine supply agreement

Novavax said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency related to its COVID-19 vaccine supply agreement.

Reuters | 1 year ago
Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
Levi & Korsinsky Reminds Novavax, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - NVAX

Levi & Korsinsky Reminds Novavax, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - NVAX

NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.

Accesswire | 1 year ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Accesswire | 1 year ago
Levi & Korsinsky Reminds Shareholders of an Investigation into Novavax, Inc. (NVAX) Regarding Potential Securities Fraud Allegations

Levi & Korsinsky Reminds Shareholders of an Investigation into Novavax, Inc. (NVAX) Regarding Potential Securities Fraud Allegations

NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.

Accesswire | 1 year ago
Novavax, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - NVAX

Novavax, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - NVAX

NEW YORK, NY / ACCESSWIRE / November 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.

Accesswire | 1 year ago
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock

Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 1 year ago
ATTENTION NVAX SHAREHOLDERS: Investors Who Lost Money on Novavax, Inc. are Urged to Contact Levi & Korsinsky about an Ongoing Investigation

ATTENTION NVAX SHAREHOLDERS: Investors Who Lost Money on Novavax, Inc. are Urged to Contact Levi & Korsinsky about an Ongoing Investigation

NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.

Accesswire | 1 year ago
Loading...
Load More